GgoogleMX first seen 4 d ago, last 21 h ago, peak #1
Bayer rises despite analyst caution after Kerendia milestone
Original: bayer
Bayer shares have moved higher even as several analysts cut their expectations for the company. The lift follows news that Bayer reached a milestone in the United States for expanding the approved uses of Kerendia, one of its key kidney-disease drugs. Markets in Germany and Latin America are tracking the stock's move, with investors weighing the positive drug-development news against more cautious analyst outlooks.
Why now: Positive regulatory news on Kerendia is driving the stock up at the same time analysts are lowering forecasts, creating debate over Bayer's outlook.
Evidence
- Bayer steigt – während Analysten ihre Erwartungen kappen · Investing.com Deutsch
- Bayer erreicht Meilenstein bei der Ausweitung der Kerendia-Indikation in den USA · MarketScreener Deutschland
Elsewhere
API: https://socialmediatrends-api.osmike.com/v1/trends/1746560